Cantor Fitzgerald Weighs in on CRNX FY2025 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXFree Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Crinetics Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($4.30) per share for the year. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share.

Crinetics Pharmaceuticals (NASDAQ:CRNXGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same period in the prior year, the business earned ($1.01) earnings per share.

Several other equities research analysts have also recently commented on the company. Jefferies Financial Group raised Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $81.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $87.00 price objective on shares of Crinetics Pharmaceuticals in a report on Monday, December 16th. Finally, Citigroup raised their target price on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, Crinetics Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $72.64.

Read Our Latest Analysis on CRNX

Crinetics Pharmaceuticals Price Performance

CRNX stock opened at $39.20 on Wednesday. Crinetics Pharmaceuticals has a fifty-two week low of $35.51 and a fifty-two week high of $62.53. The business has a fifty day moving average price of $51.19 and a 200 day moving average price of $52.77. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of -10.51 and a beta of 0.60.

Insider Activity

In related news, COO Jeff E. Knight sold 501 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.52, for a total value of $28,316.52. Following the transaction, the chief operating officer now directly owns 51,653 shares of the company’s stock, valued at approximately $2,919,427.56. The trade was a 0.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its position in Crinetics Pharmaceuticals by 3.3% during the 2nd quarter. AQR Capital Management LLC now owns 7,126 shares of the company’s stock valued at $319,000 after purchasing an additional 227 shares during the last quarter. US Bancorp DE raised its stake in Crinetics Pharmaceuticals by 3.4% during the 3rd quarter. US Bancorp DE now owns 11,488 shares of the company’s stock valued at $587,000 after buying an additional 373 shares during the last quarter. KBC Group NV grew its position in Crinetics Pharmaceuticals by 22.8% during the third quarter. KBC Group NV now owns 2,193 shares of the company’s stock valued at $112,000 after buying an additional 407 shares during the period. Amalgamated Bank lifted its position in shares of Crinetics Pharmaceuticals by 20.8% during the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock valued at $121,000 after buying an additional 464 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Crinetics Pharmaceuticals by 2.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 20,633 shares of the company’s stock valued at $1,054,000 after acquiring an additional 505 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company’s stock.

About Crinetics Pharmaceuticals

(Get Free Report)

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

Featured Stories

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.